Effect of Ginkgo biloba (EGb 761) on treadmill walking time among adults with peripheral artery disease: A randomized clinical trial

Journal of Cardiopulmonary Rehabilitation and Prevention

Volumn 28, Issue 4, 2008, Pages 258-265

  Gardner, Christopher D ^a   Taylor Piliae, Ruth E ^a   Kiazand, Alexandre ^a   Nicholus, Joel ^a   Rigby, Alison J ^a   Farquhar, John W ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Claudication; Ginkgo biloba; Peripheral artery disease; Treadmill time

Indexed keywords

APOLIPOPROTEIN B100; EPITOPE; GINKGO BILOBA EXTRACT; IMMUNOGLOBULIN; IMMUNOGLOBULIN M; MALONALDEHYDE; MONOCLONAL ANTIBODY; OXIDIZED LOW DENSITY LIPOPROTEIN; PLACEBO; CARDIOVASCULAR AGENT; GINKGO BILOBA EXTRACT 761; PLANT EXTRACT;

AGED; ANTIBODY BLOOD LEVEL; ANTIGEN BINDING; ANTIOXIDANT ACTIVITY; ARTERY DISEASE; ARTICLE; BLOOD SAMPLING; CLAUDICATION; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; EXERCISE TEST; FATIGUE; GINKGO BILOBA; HUMAN; LEG CRAMP; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PAIN ASSESSMENT; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SHORT FORM 36; SYSTOLIC BLOOD PRESSURE; TREADMILL EXERCISE; TREATMENT DURATION; VASODILATATION; WALKING DIFFICULTY; COMPARATIVE STUDY; FEMALE; FOLLOW UP; MALE; METHODOLOGY; PATHOPHYSIOLOGY; PERIPHERAL VASCULAR DISEASE; PHYSIOLOGY; TREATMENT OUTCOME; WALKING;

AGED; CARDIOVASCULAR AGENTS; DOUBLE-BLIND METHOD; EXERCISE TEST; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; PERIPHERAL VASCULAR DISEASES; PLANT EXTRACTS; QUALITY OF LIFE; QUESTIONNAIRES; TREATMENT OUTCOME; WALKING;

EID: 54549127213     PISSN: 19327501     EISSN: 1932751X     Source Type: Journal    
DOI: 10.1097/01.HCR.0000327184.51992.b8     Document Type: Article

References (40)

1. Kelly JP, Kaufman DW, Kelley K, Rosenberg L, Anderson TE, Mitchell AA. Recent trends in use of herbal and other natural products. Arch Intern Med. 2005;165:281-286.
2. Diamond BJ, Shiflett SC, Feiwel N, et al. Ginkgo biloba extract: mechanisms and clinical indications. Arch Phys Med Rehabil. 2000;81:668-678.
3. Pittler MH, Ernst E. Ginkgo biloba extract for the treatment of intermittent claudication: a meta-analysis of randomized trials. Am J Med. 2000;108:276-281.
4. Sierpina VS, Wollschlaeger B, Blumenthal M. Ginkgo biloba. Am Fam Phys. 2003;68:923-926.
5. Mehlsen J, Drabaek H, Wiinberg N, Winther K. Effects of a Ginkgo biloba extract on forearm haemodynamics in healthy volunteers. Clin Physiol Funct Imaging. 2002;22:375-378.
6. Liebgott T, Miollan M, Berchadsky Y, Drieu K, Culcasi M, Pietri S. Complementary cardioprotective effects of flavonoid metabolites and terpenoid constituents of Ginkgo biloba extract (EGb 761) during ischemia and reperfusion. Basic Res Cardiol. 2000;95:368-377.
7. Kubota Y, Tanaka N, Umegaki K, et al. Ginkgo biloba extract-induced relaxation of rat aorta is associated with increase in endothelial intracellular calcium level. Life Sci. 2001;69: 2327-2336.
8. Akiba S, Kawauchi T, Oka T, Hashizume T, Sato T. Inhibitory effect of the leaf extract of Ginkgo biloba L. on oxidative stress-induced platelet aggregation. Biochem Mol Biol Int. 1998;46:1243-1248.
9. Chung KF, Dent G, McCusker M, Guinot P, Page CP, Barnes PJ. Effect of a ginkgolide mixture (BN 52063) in antagonising skin and platelet responses to platelet activating factor in man. Lancet. 1987;1(8527):248-251.
10. Guinot P, Caffrey E, Lambe R, Darragh A. Tanakan inhibits platelet-activating-factor-induced platelet aggregation in healthy male volunteers. Haemostasis. 1989;19:219-223.
11. Kudolo GB, Dorsey S, Blodgett J. Effect of the ingestion of Ginkgo biloba extract on platelet aggregation and urinary prostanoid excretion in healthy and type 2 diabetic subjects. Thromb Res. 2002;108(2/3):151-160.
12. Bal Dit Sollier C, Caplain H, Drouet L. No alteration in platelet function or coagulation induced by EGb761 in a controlled study. Clin Lab Haematol. 2003;25:251-253.
13. Braquet P. Cedemin, a Ginkgo biloba extract, should not be considered as a PAF antagonist. Am J Gastroenterol. 1993; 88:2138.
14. Koch E. Inhibition of platelet activating factor (PAF)-induced aggregation of human thrombocytes by ginkgolides: considerations on possible bleeding complications after oral intake of Ginkgo biloba extracts. Phytomedicine. 2005;12(1/2):10-16.
15. Kohler S, Funk P, Kieser M. Influence of a 7-day treatment with Ginkgo biloba special extract EGb 761 on bleeding time and coagulation: a randomized, placebo-controlled, double-blind study in healthy volunteers. Blood Coagul Fibrinolysis. 2004;15:303-309.
16. Sacks D, Bakal CW, Beatty PT, et al. Position statement on the use of the ankle brachial index in the evaluation of patients with peripheral vascular disease. A consensus statement developed by the Standards Division of the Society of Interventional Radiology. J Vasc Interv Radiol. 2003;14(9, pt 2):S389.
17. Mohler ER III. Peripheral arterial disease: identification and implications. Arch Intern Med. 2003;163:2306-2314.
18. World Medical Association Declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. JAMA. 1997;277:925-926.
19. American College of Sports Medicine. Guidelines for Exercise Testing and Prescription. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2000.
20. American College of Sports Medicine. Resource Manual for Guidelines for Prescription Testing and Prescription. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2001.
21. Gardner AW, Skinner JS, Smith LK. Effects of handrail support on claudication and hemodynamic responses to single-stage and progressive treadmill protocols in peripheral vascular occlusive disease. Am J Cardiol. 1991;68:99-105.
22. Corretti MC, Anderson TJ, Benjamin EJ, et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol. 2002;39:257-265.
23. Rodenburg J, Vissers MN, Wiegman A, et al. Oxidized low-density lipoprotein in children with familial hypercholesterolemia and unaffected siblings: effect of pravastatin. J Am Coll Cardiol. 2006;47:1803-1810.
24. Tsimikas S, Bergmark C, Beyer RW, et al. Temporal increases in plasma markers of oxidized low-density lipoprotein strongly reflect the presence of acute coronary syndromes. J Am Coll Cardiol. 2003;41:360-370.
25. Tsimikas S, Witztum JL, Miller ER, et al. High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial. Circulation. 2004;110:1406-1412.
26. Regensteiner JG, Steiner JF, Panzer RJ, Hiatt WR. Evaluation of walking impairment by questionnaire in patients with peripheral arterial disease. J Vasc Med Biol. 1990;2:142-152.
27. McDermott MM, Liu K, Guralnik JM, Martin GJ, Criqui MH, Greenland P. Measurement of walking endurance and walking velocity with questionnaire: validation of the Walking Impairment Questionnaire in men and women with peripheral arterial disease. J Vasc Surg. 1998;28:1072-1081.
28. Regensteiner JG, Steiner JF, Hiatt WR. Exercise training improves functional status in patients with peripheral arterial disease. J Vasc Surg. 1996;23:104-115.
29. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36); part I: conceptual framework and item selection. Med Care. 1992;30:473-483.
30. Izquierdo-Porrera AM, Gardner AW, Bradham DD, et al. Relationship between objective measures of peripheral arterial disease severity to self-reported quality of life in older adults with intermittent claudication. J Vasc Surg. 2005;41:625-630.
31. McDermott MM, Mehta S, Liu K, et al. Leg symptoms, the ankle-brachial index, and walking ability in patients with peripheral arterial disease. J Gen Intern Med. 1999;14:173-181.
32. Bohmer D, Kalinski S, Michaelis P, Szogy A. Behandlung der PAVK mit ginkgo-biloba-extrakt (GBE) oder pentoxifyllin. Herz Kreislauf. 1988;20:5-8.
33. Hiatt WR. The US experience with cilostazol in treating intermittent claudication. Atheroscler Suppl. 2005;6:21-31.
34. Falcone RA, Hirsch AT, Regensteiner JG, et al. Peripheral arterial disease rehabilitation: a review. J Cardiopulm Rehabil. 2003;23:170-175.
35. Leng GC, Fowler B, Ernst E. Exercise for intermittent claudication. Cochrane Database Syst Rev. 2000(2):CD000990.
36. Auguet M, Delaflotte S, Chabrier PE, Braquet P. Ginkgo Biloba Extract (EGb 761) and the Regulation of Vascular Tone. Vol 3. Paris: Elsevier; 1994.
37. Koltermann A, Hartkorn A, Koch E, Furst R, Vollmar AM, Zahler S. Ginkgo biloba extract EGb((R)) 761 increases endothelial nitric oxide production in vitro and in vivo. Cell Mol Life Sci. 2007;64:1715-1722.
38. Maitra I, Marcocci L, Droy-Lefaix MT, Packer L. Peroxyl radical scavenging activity of Ginkgo biloba extract EGb 761. Biochem Pharmacol. 1995;49:1649-1655.
39. Sener G, Sehirli O, Tozan A, Velioglu-Ovunc A, Gedik N, Omurtag GZ. Ginkgo biloba extract protects against mercury(II)-induced oxidative tissue damage in rats. Food Chem Toxicol. 2007;45:543-550.
40. Hackam DG, Goodman SG, Anand SS. Management of risk in peripheral artery disease: recent therapeutic advances. Am Heart J. 2005;150:35-40.